Still no $SNY KYNAMRO mipomersen NDA filed, this is getting fishy pretty soon. "Finishing touches" in late Nov before "data glitch" $ISIS

$OGXI PRs on bladder http://t.co/JFzdIG3s and prostate http://t.co/BAHFIdEU HSP27 antisense at #ASCOGU - webcast today. $ISIS

Under $10 long intraday setups on market and sector confirmation for next session only: $DHX, $ISIS, $KEM, $OPK

$ISIS : Research & Development Day Pipeline Recap - https://t.co/ILodAYr3

New post: $ISIS research & development day recap of several pipeline antisense drugs and my current sentiment: http://t.co/3liNG1XU

$ALNY files IND for second gen TTR RNAi program. p1 data in 3q12. switched to healthy volunteers this time (faster, same as $ISIS did)

Didn't see anyone mention it, but $ISIS also announced today that they killed SGLT2 program - phase 1 data was much-delayed and never came

$ISIS reports TTR phase 1 data - hopefully more details at todays R&D Day presentation: http://t.co/qj6DkXjg

$ISIS getting $29M from $BIIB for option to SMA drug <2 months after Roche shelled out $30M up front for PTC’s SMA program

rare disease strikes again. $BIIB pays $ISIS 29m upfront for phase 1 SMA antisense drug. http://t.co/39WqXLvT

$isis Initiates Phase 1 Clinical Trial of ISIS-FGFR4Rx a Peripherally Acting Drug to Treat Obesity